Dipred0.05%

Dipred is a potent topical corticosteroid ophthalmic emulsion indicated for:

• Treatment of inflammation and pain associated with ocular surgery (FDA-approved, established use) - used post-operatively (e.g., after cataract surgery) to control surgically induced inflammation and pain.
• Treatment of endogenous anterior uveitis (FDA-approved, established use) - a non-infectious inflammatory condition of the iris and anterior chamber of the eye.

Dipred is not indicated for infectious causes of ocular inflammation unless used together with an appropriate anti-infective agent, and it is not intended for self-directed long-term use outside a physician's supervision.

Each mL of ophthalmic emulsion contains Difluprednate 0.05% w/v as the active ingredient, in a sterile oil-in-water emulsion base with inactive ingredients such as boric acid, castor oil, glycerin, polysorbate 80, and water for injection, with pH adjusted using sodium hydroxide/hydrochloric acid as needed.

Dipred is a synthetic difluorinated derivative of prednisolone, formulated as a 0.05% topical ophthalmic emulsion. It is one of the most potent topical ocular corticosteroids available, used to suppress inflammation and reduce pain following ocular surgery and in endogenous anterior uveitis. Its emulsion-based formulation is designed to enhance corneal penetration, allowing effective anti-inflammatory activity in the anterior segment of the eye.

Difluprednate is a difluorinated corticosteroid that, after conversion to its active metabolite difluprednate 21-butyrate in ocular tissue, binds to glucocorticoid receptors to induce anti-inflammatory proteins (such as lipocortins) and suppress the release of arachidonic acid, thereby inhibiting the synthesis of prostaglandins and leukotrienes. This reduces inflammatory mediators, decreases capillary permeability, and suppresses migration of inflammatory cells, leading to reduced ocular inflammation, pain, edema, and hyperemia. Due to its high receptor-binding affinity and the emulsion vehicle's enhanced corneal penetration, Difluprednate exhibits greater relative potency than many other topical ocular steroids at equivalent concentrations.

For topical ophthalmic (eye drop) use only. Not for injection or oral use. Shake the bottle well before each use. Wash hands before use, tilt the head back, pull down the lower eyelid to form a pouch, and instill one drop without letting the dropper tip touch the eye or any surface. Close the eye gently for 1-2 minutes after instillation. If wearing contact lenses, remove them before instillation and wait at least 10 minutes before reinserting.

No formal, well-characterized clinically significant drug-drug interaction studies have been conducted for Dipred due to its minimal systemic absorption with topical ocular use. However, concurrent use of other topical ophthalmic corticosteroids or immunosuppressive ophthalmic agents may have additive effects on intraocular pressure and infection risk, so such combinations should be used only under close ophthalmologic supervision. When other topical eye medications are used concurrently, they should be administered at least 5 minutes apart from Dipred to prevent dilution or washout.

The most common adverse reactions reported with Dipred include:

• Eye pain
• Blurred vision
• Photophobia (light sensitivity)
• Elevated intraocular pressure
• Conjunctival hyperemia and edema
• Corneal edema
• Posterior capsule opacification/cataract
• Anterior chamber inflammation or cells
• Blepharitis and eye irritation
• Headache (less commonly)

Serious but less common effects include glaucoma, secondary ocular infection, delayed wound healing, and (rarely) corneal or scleral perforation in predisposed eyes - see Precautions and Warnings.

Pregnancy: There are no adequate and well-controlled studies of Dipred in pregnant women. Although systemic absorption after topical ocular administration is expected to be minimal, corticosteroids have been associated with fetal effects in animal reproduction studies at systemic exposures. Dipred should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether topically administered Dipred is excreted in human milk in clinically relevant amounts. Because systemic absorption is minimal, risk to a nursing infant is expected to be low, but caution should be exercised and a physician consulted before use during breastfeeding.

Use of Dipred requires ongoing ophthalmologic supervision, particularly with prolonged use, due to the following risks:

• Elevated intraocular pressure/glaucoma: Prolonged use (generally beyond 10 days) can raise intraocular pressure and may lead to glaucoma with possible optic nerve damage and visual field defects; intraocular pressure should be monitored periodically, especially in patients with a history of glaucoma or steroid-induced IOP response.
• Cataract formation: Long-term corticosteroid use may lead to posterior subcapsular cataract formation.
• Delayed wound healing: May slow healing and increase the incidence of thin or bleb-associated complications following ocular surgery.
• Masking or exacerbating infection: Corticosteroids may suppress the clinical signs of infection, permitting or exacerbating secondary bacterial, viral, or fungal ocular infections; use with caution in the presence of any suspected infection and only alongside appropriate anti-infective therapy where needed.
• Not for self-directed extended use - the prescribed course and follow-up ophthalmic examinations must be adhered to given the potency of this corticosteroid.
• Remove contact lenses before instillation; reinsertion may resume after at least 10 minutes.

Topical ocular overdose of Dipred is unlikely to cause acute systemic toxicity, but excessive or prolonged use may worsen local ocular side effects such as elevated intraocular pressure, corneal thinning, or delayed healing. If accidental oral ingestion occurs or excessive instillation causes significant ocular or systemic symptoms, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. The affected eye(s) may be flushed gently with clean water in case of accidental excess instillation, followed promptly by professional medical evaluation.

Store at room temperature, ideally 20-25°C (68-77°F); brief excursions to 15-30°C are permitted. Protect from light and keep the bottle in its original carton when not in use. Do not freeze. Shake well before each use. Keep out of reach of children.

Pediatric use: Safety and effectiveness of Dipred in pediatric patients below 18 years have not been established through large controlled trials; limited data in infants and toddlers suggest a safety profile comparable to other ophthalmic corticosteroids, but use in children should be under close specialist supervision. See Pediatric Uses for more detail.

Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Hepatic/Renal impairment: No specific dose adjustment data are available; given minimal systemic absorption with topical ocular use, clinically significant effects are not expected, but use with the same precautions as in other patients.

Corticosteroid; Ophthalmic anti-inflammatory agent; Difluorinated glucocorticoid.

C

The safety and effectiveness of Dipred in pediatric patients have not been fully established in large randomized controlled trials. Limited clinical experience in infants and toddlers (including use after pediatric cataract surgery) has shown a safety profile generally comparable to other ophthalmic corticosteroids such as prednisolone acetate, but pediatric patients may be more sensitive to steroid-induced elevations in intraocular pressure. Dipred should be used in children only under close ophthalmologic supervision, with appropriate monitoring of intraocular pressure and periodic eye examinations, and only when a physician determines the potential benefit outweighs the risk.